High-dose eicosapentaenoic acid and docosahexaenoic acid provided additional benefit to statins in preventing progression of fibrous coronary plaque in individuals adherent to therapy with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, a recent study found. 285 participants with stable coronary artery disease (CAD) on statins were randomized to omega-3 ethyl-ester or no omega-3 (control) for 30 months. Mean age of participants was 63.0 years; mean LDL-C ≤80 mg/dL. Researchers found:
- High dose eicosapentaenoic acid and docosahexaenoic acid (3.36 g daily) provided additional benefit to statins in preventing progression of fibrous coronary plaque over 30 months.
- Participants aged <64.2 years had significantly less progression of noncalcified plaque and fibrous, calcified, and total plaque volume compared with older participants.
- Eicosapentaenoic acid and docosahexaenoic acid prevented plaque progression in those on low‐intensity statin, but not high‐intensity statin.
Alfaddagh A, Elajami TK, Ashfaque H, Saleh M, Bistrian BR, Welty FK. Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: A randomized clinical trial. [Published online ahead of print December 15, 2017]. J Am Heart Assoc. doi:10.1161/JAHA.117.006981.
This Week's Must Reads
Omega-3 Fatty Acids for Prevention of CVD, Cochrane Library; ePub 2018 Jul 18; Abdelhamid, et al
Elevated hs-CRP Among Patients with Prior MI, Am Heart J; ePub 2018 Jul 26; Pagidipati, et al
Catheter Ablation for Ventricular Arrhythmias, Am J Cardiol; ePub 2018 Jul 18; Ogunbayo, et al
PIs and CV Outcomes in Patients with HIV and HF, J Am Coll Cardiol; 2018 Jul; Alvi, Neilan, et al
Hypertension in Blacks Higher Through Middle Age, J Am Heart Assoc; ePub 2018 Jul 11; Thomas, et al
Must Reads in Hypercholesterolemia
Racial Differences in Statin Use, JAMA Cardiol; ePub 2018 Jun 13; Nanna, et al
LLT Use in Patients with Elevated LDL-C, Circ Cardiovasc Qual Outcomes; ePub 2018 May 10; Virani, et al
Evolocumab in Differing Patient Populations , J Pharmacokinet Pharmacodyn; ePub 2018 May 7; Kuchimanchi, et al
LDL-C Targets in Elderly Statin Users After ACS, J Am Heart Assoc; ePub 2018 May 12; Alter, et al
Patient Perspectives on Statin Therapy, Clin Cardiol; ePub 2018 May 10; Brinton